VSV-02
AXP000133.1 · Oncolytic virus
- Platform
- vesicular stomatitis virus (attenuated, bispecific antibody-armed)
- Originator
- Shanghai Rongrui Pharmaceutical Technology
- Sponsor
- Shanghai Rongrui Pharmaceutical Technology
Names
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Strain
- attenuated
- Replication
- replicating
- Modifications
- attenuated VSV encoding a CD3/PD-L1 bispecific antibody
- Transgenes
- CD3/PD-L1 bispecific antibody
- Route
- intravenous, intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | Recruiting | Phase 1 | 2025-09-22 | 2026-09-30 | 6 | Advanced Solid Tumor; Breast Cancer; Cancer Treatment; Immunotherapy; Lung Cancer; Melanoma |
Recent changes
No changes recorded in its trials yet.
Notes
Attenuated VSV engineered to encode a CD3/PD-L1 bispecific antibody, per the NCT07260591 registration. Compassionate-use/phase 1 study at the First Affiliated Hospital of Xinxiang Medical College, recruiting from December 2025; concurrent intravenous and intratumoral dosing. Attenuating mutations not described.
How to cite
VSV-02 (AXP000133.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000133.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.